Shai Novik, Executive Chairman of the Board
Mr. Novik founded PROLOR Biotech in 2005, and has served as its President until 2014. PROLOR Biotech was listed on NYSE in 2010 and was sold in 2013, the second largest biotech exit in the history of Israeli biotech.
Mr. Novik previously served as Chief Operating Officer and Head of Strategic Planning of THCG, Inc., a technology and life sciences investment company. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. THCG’s own portfolio included several life sciences and medical devices companies. Mr. Novik received his M.B.A, with distinction, from the Cornell University.
Bernd Kirschbaum, Ph.D.
Mr. Kirschbaum served as Executive Vice President & Member of the Board at Merck Serono, Head of Global Research & Early Development reporting to the CEO of Merck Serono. Led a global team of >1,200 employees, with a 400 million Euro annual budget. Mr. Kirschbaum has significant expertise in a broad range of diseases areas including Rheumatology/Immunology, Thrombosis, Cardiometabolic Diseases, Oncology, Neurology. He has successfully participated in the profiling of several drugs in their course to the market or during market expansion including Arava, Velcade, Lovenox, Erbitux, and Avelumab. Mr. Kirschbaum led drug portfolio re-allocation with focus on the therapeutic areas: Oncology, Neurodegenerative Diseases (MS, Alzheimer, Parkinson), Autoimmune and Inflammatory Diseases. Some remaining research activities in Fertility, mainly focusing on embryo technologies. He implemented the new Merck Serono research organization, including an exploratory medicine department and all non-clinical development functions (Toxicology, General & Safety Pharmacology, CMC Development, DMPK). Previously, Mr. Kirschbaum was Vice President Discovery Research, Global Head of Thrombosis and Angiogenesis at Sanofi-Aventis; Vice President, Drug Innovation and Approval at t Sanofi-Aventis; and Head of the Center for Applied Genomics (TCAG) at HMR. Mr. Kirschbaum earned his Ph.D. in biochemistry, summa cum laude, from the University of Konstanz, Germany; was a postdoctoral fellow with Dr. R.G. Roeder, at the Rockefeller University in New York, and a Research Associate with Dr. M. Buckingham at Institut Pasteur in Paris.
Abraham (Avri) Havron, Ph.D.
Served as the CEO of PROLOR Biotech Inc. from 2005 through 2013. Dr. Havron is a 35-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories (a subsidiary of Serono) from 1980 to 1987, and headed the development the multiple sclerosis drug REBIF, with current sales of more than $1.5 billion annually. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Dr. Havron’s managerial responsibilities included the co-development of several therapeutic proteins and other bio-pharmaceuticals currently in the market, including recombinant human growth hormone (BioTropin), recombinant Hepatitis B Vaccine (Bio-Hep-B), recombinant Beta Interferon (REBIF), recombinant human insulin and hyaluronic acid for ophthalmic and orthopedic applications. Dr. Havron earned his Ph.D. in Bio-Organic Chemistry from the Weizmann Institute of Science, and served as a Research Fellow in the Harvard Medical School, Department of Radiology.
Mr. Lee is a Executive Director of the Investment Department & Head of U.S. Branch at Korea Investment Partners Co. Ltd., the largest venture capital fund in Korea. He is responsible to sourcing & evaluation of start-up companies, investment and participation in business development and growth expansion of the fund’s investments in the U.S. and Europe. Previously, Mr. Lee was General Manager of the MSC Department at Samsung Electronics, responsible for strategic and business planning; and Vice president, CTO & Foreign Marketing Group Leader at Polidigm Co. Ltd. Mr. Lee received his B.Sc. and M.Sc. from Seoul National University, Department of Control and Instrumentation.
Hyun Gyu Lee, Ph.D., M.D.
Mr. Lee is the Executive Director, Investment Division, of Korea Investment Partners Co., Ltd., the largest venture capital fund in Korea. He was previously Research Assistant Professor with the Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Yonsei University, College of medicine in Seoul, Korea. He received his Ph.D. in Immuno-Pathology from the Seoul National University, College of Medicine in Seoul, Korea, and his M.D. degree from Seoul National University, College of Medicine in Seoul, Korea.
Gili Hart, Ph.D.
General Manager of OPKO Biologics Ltd (f.k.a. PROLOR Biotech Inc.). Dr. Hart has held various positions in PROLOR Biotech and has been leading the pre-clinical, clinical and pharmacological activities there since 2008. Dr. Hart was a research fellow in the Immunology Department of Yale University in Connecticut from 2005 to 2007 and a research fellow at the Immunology Department of the Weizmann Institute of Science in Israel. Dr. Hart received her Ph.D. with distinction from the Immunology Department of the Weizmann Institute of Science in immunology, and a M.s. degree in Biotechnology Engineering, summa cum laude, from the Technion Institute in Israel. Dr. Hart has published numerous papers and patents, in each case focusing on autoimmunity disease and immune system activation.
With more than 20 years of experience in VC and Private Equity as an entrepreneur, corporate finance advisor, senior executive and an investor, Baruch has developed a large network of contacts across the globe. Since 2010, Baruch and has been involved in turn arounds through active management and PE investments of high yield opportunities. In this capacity, Baruch is active in investing in companies with annual revenues of at least USD 100 million in special situations and took part in the successful turnarounds of, inter alia, Hemaclear (www.hemaclear.com), Apnano (www.nisusacorp.com) and HBL (www.hbl.co.il). Early in his career, Baruch was active in oil and gas exploration in Israel. In that capacity he obtained, developed, and sold the rights to an Israeli oil and gas exploration license, the Megiddo Prospect, to Ultra Petroleum (AMEX: UPL). In 1997, Baruch founded E*TRADE Israel (www.etrade.com). Obtaining a license from E*TRADE, Baruch put together a core management team and headed several successful rounds of financing. Following E*TRADE, Baruch was Head of Corporate Finance at Fantine Capital. Baruch holds an LLB Degree (Hons.) from Reading University, UK.
Michel was the co founder and managed Agate Medical Investments and Agate MaC VC funds, with over $100M under management. His portfolio companies have attracted investments from leading global and Chinese companies including Boston Scientific, Johnson & Johnson, Medtronic, Haisco, Longtech, Xio • Currently Mr. Habib serves on the board of several investment companies and startups, including Xenia Ventures, Kahr Medical (Chairman), Enlivex, Cellcure, Bioprotect and Ornim Medical • Prior to that he managed Matar Capital Advisors, a venture boutique. Michel Habib served for close to 4 years as Elron’s Business Development Director, focusing on the Medical Devices sector. Prior to Elron, he established and managed the investment banking activity of ING Barings in Israel. Formerly, he served as Vice President Investment Banking at Cukierman & Co. where he led private placements and IPOs in Europe • During the 90’s Mr. Habib served as diplomat in Israel’s foreign service, where he served as Economic Consul in Boston, and earlier as the first Commercial Attache to Seoul, S.Korea. As Navy Officer (Captain Res.) in the IDF, he was involved in the development of advanced Naval warfare systems for the Navy’s elite unit • Mr. Habib holds an Aeronautical Engineering degree from the Technion-Israel Institute of Technology, and is a graduate from Harvard Law School Executive Program On Negotiation (PON). He is a graduate from the foreign service cadet school, and member of the Technion Alumni “100 Club”. Mr. Habib was born in Paris, France, immigrated to Israel in 1973.